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ABSTRACr 
Pharmacokinetics of oxytetracycline (OTC) was studied in 
swamp 
mg/kg 
buffalo heifers and cows after a single injection of 
OTC hydrochloride intravenously and OTC long acting 
20 
(LA) 
formulation (Terramycin/LA, Pfizer) intramuscularly using a cross­
over study. The concentration of OTC in serum samples was mea­
sured by a bioassay technique using Bacillus cereus (ATCC 11778) 
as the test organism. 
The disposition curve for oxytetracycline activities after 
intravenous administration was best described by a two-compart­
ment open model. The serum concentrations at time zero, c8p, for 
buffalo cows and buffalo heifers were 61 . 37+19 . 62 mcg/ml and 
(ix) 
33 . 09+9 . 93 mcg/ml respectively .  The elimination half-lives for 
buffalo cows (10 . 13+2 . 72 h) and heifers ( 8 . 72+2 . 14 h) after intra-
venous injection of the drug were not significantly different 
(P)0 . 05). The apparent volume of distribution was significantly 
higher in buffalo cows ( 2 . 84+0. 46 L/kg) than in heifers ( 2 . 0+0 . 42 
L/kg) but the total body clearance did not differ significantly 
(P>O . OS) . 
Following a single intramuscular injection of OTC-LA formu-
lation only one rate constant of absorption was noted in buffalo 
cows (ka-O. OS h) but two rate constants of absorption were noted 
for heifers - a fast rate (ka1 -3 . 62 h) and a slow rate (ka2 -O .04 
h). The peak serum concentration of OTC for buffalo cows was 
4 . S6+1 . 48 mcg/ml at 4 . 67+1. 91 hours and for buffalo heifers was 
4 . 40+ 0 . S7 mcg/ml at 1 . 67+0 . 26 hours . The bioavailability of OTC 
was 64 and 24 per cent for buffalo cows and heifers respectively . 
Plasma concentrations above O .S  mcg/ml were maintained for appro-
ximately SO-60 hours . The minimum inhibition concentration (MIC) 
for eleven isolates from diseased buffaloes ranged from 0 . 2S to 
4 . 0  mcg/ml . 
For the swamp buffalo OTC-LA is recommended at a dosing rate 
of 20 mg/kg injected intramuscularly at 48-hour dosage inter­
vals for highly susceptible organisms (MIC<l mcg/ml) .  However it 
is preferable to use the conventional OTC formulation intramuscu-
larly for less susceptible organisms (MIC>2 mcg/ml) . 
(x)  
CHAPTER I 
INTRODUCTION 
Water buffaloes ( Bubalus bubalis) may be classified into 
river and swamp types according to their wallowing habits . Water 
buffaloes are among the most important domestic ruminants provi­
ding draft power , milk and meat in over 40 countries . The world 
buffalo population is approximately 150 million or one-eighth of 
the population of cattle . Over 95 per cent of the buffaloes in 
Malaysia are of the swamp type . They are primarily used for draft 
power and are concentrated in the rice growing areas where they 
are utilized for ploughing , harrowing and puddling of rice fields 
before planting . At the end of their working life , swamp buffa­
loes provide about half the present meat supply in Malaysia . 
The important bacterial diseases of buffaloes include haemo­
rrhagic septicaemia (Pasteurella multocida) , infectious keratitis 
(Haemophilus bovis) ,  suppurative pneumonia (Strep. pyogenes and 
Pasteurella multocida) and arthritis (�coli and Corynebacte­
rium pyogenes) .  These diseases particularly haemorrhagic septi­
caemia cause severe economic losses to the country. 
There is a lack of accurate information on the use of anti­
biotic therapy in the water buffalo . Much of our knowledge on 
antibiotic therapy in the water buffalo is based on information 
from cattle . Pharmacokinetic studies are essential to establish 
1 
2 
dosage regimens adequate for producing effective antimicrobial 
drug concentrations in vivo . --- This information is of importance 
especially to veterinarians who have been treating diseased 
buffaloes with dosages recommended for cattle . 
Oxytetracycline (OTC) is an important antimicrobial drug and 
is commonly used in veterinary medicine . Until recently , paren-
teral OTC therapy has involved the daily administration over 
several days . A depot formulation of oxytetracycline containing 
200 mg/ml of OTC (Terramycin-LA, Pfizer)allows a reduction in the 
frequency of administration . The main advantage of this product 
is that a single dose (20 mg/kg) sustains effective levels for 
over three to five days in cattle and sheep . 
OTC-LA would be a very valuable antibiotic in the water 
buffalo as it would overcome the problem of daily administration 
of OTC to diseased buffaloes under range conditions where restrai-
ning facilities are inadequate .  However , very few studies have 
been been conducted in the buffalo to determine effective blood 
levels of OTC-LA . There is also no information on the absorp-
tion , distribution and elimination of oxytetracycline in swamp 
buffaloes after parenteral administration . 
This study was therefore conducted in healthy female swamp 
buffaloes : 
a .  To determine the disposition kinetics of oxytetracycline 
hydrochloride following intravenous injection of a single 
dose . 
b .  To ascertain the rate of absorption and systemic availa-
bility of OTC following administration of OTC-LA by the 
intramuscular route . 
3 
c .  To establish minimum inhibitory concentrations for diffe­
rent bacterial isolates from diseased buffaloes . 
d .  To recommend dosing rate for OTC-LA that would maintain 
"effective" serum oxytetracycline concentrations in the 
swamp buffalo . 
CHAPTER II 
REVIEW OF LITERATURE 
PHARMACOKINETICS 
Pharmacokinetics deals in part with the mathematical descrip­
tion of the time course of drug absorption , distribution and 
elimination by means of a suitable model (Levy and Gibaldi , 
1972) . 
To facilitate the study of the pharmacokinetic behaviour of 
drugs ,  the body is depicted as a system made up of one , two or 
three distribution compartment open models (Figure 1 ) .  The prin­
ciple adopted in analysing the serum concentration-time profiles 
is to employ the pharmacokinetic model with the least number of 
compartments that can adequately describe the data. 
If a drug distributes very rapidly relative to the rate of 
elimination , the disposition kinetics of the drug behaves as a 
single homogeneous distribution and the one-compartment open 
model is applied (Figure 1a) . This model assumes that a change in 
the drug concentration in one tissue is accompanied by a corres­
ponding change in drug concentration in all other tissues ( in­
cluding plasma) at the same time . The following expression satis­
fies the one-compartment open model (Baggot , 1977) : 
-pt 
Cp = Be ( 1 ) 
where Cp is the concentration of the drug in plasma at any time 
4 
5 
A 
Elimination 
B t 
8, K12 :.. K21 
Ke' 
Elimination 
c 
t 
L K13 ,8, K12 ::=. K31 K21 
Ke. 
Elimination 
FIGURE 1 :  DIAGRAMMATIC PRESENTATION OF COMPARTMENTAL 
PHARMACOKINETIC MODELS 
A :  One-compartment model; B :  Two-compartment model; 
C: Three-compartment model 
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t ,  B (mcg/ml) i s  zero-time intercept extrapolated from the over­
all elimination rate constant "13" and "ell the base of the natural 
logarithm . Drugs that can be adequately described by a one­
compartment open model include amphetamine (Baggot and Davis , 
1973) , chloramphanicol (Davis � al . ,  1972) and quinidine (Neff 
et al . ,  1 972) . 
Disposition kinetics of many drugs including erythromycin 
and tylosin (Baggot and Gingerich , 1976) , ketamine (Baggot and 
Blake , 1976) , trimethoprim (Alexander and Collett , 1974) , can be 
described by a two-compartment open model (Figure Ib) . 
It is assumed that a drug introduced into the central com­
partment , which consists of blood plasma and the extracellular 
fluid of highly perfused organs such as lungs , liver , heart and 
kidneys , distributes instantaneously and homogeneously , and that 
it is eliminated exclusively from the central compartment . Dis­
tribution into the second or peripheral ( tissue ) compartment , 
which consists of less perfused tissues such as muscle ,  skin and 
body fat , occurs more slowly . A two-compartment open model can be 
described by the following expression: 
-at 
Cp = Ae 
-f3t 
+ Be (2 )  
where Cp is  the concentration of  the drug in  the plasma at any 
time t ,  A and B (mcg/ml) are extrapolated intercepts "a" and "fJ" 
are the rate constants for the distribution and elimination 
phases respectively , expressed in unit reciprocal time ( h-1) ,  and 
"e" represents the base of the natural logarithm (Baggot , 1978) . 
The sum of A and B (mcg/ml) gives the plasma concentration at 
time zero . 
7 
Disposition kinetics of a few drugs such as sulphadimetho­
xine (Boxenbaum and Kaplan , 1975) and oxytetracycline in dogs 
(Baggot et al . ,  1977) can be described by a three-compartment 
open model (Figure lc) as follows: 
-nt 
Cp = Pe 
-at 
+ Ae 
-{Jt 
+ Be  (3)  
where "nil and "a" ( in unit reciprocal time) are the rate con­
stants of distribution phases and "[3" ( in unit reciprocal time) 
is the rate constant of elimination phase , P ,  A ,  and B (mcg/ml) 
are zero-time extrapolated intercepts respectively ,  and "e" is 
the base of the natural logarithm . The individual rate constants 
associated with three-compartment open model (k1 2, k21 , k1 3 , k31 
and k el ) can be calculated (Gibaldi and Perrier , 1975) . 
The rate constants of the absorption and the elimination of 
a drug are assumed to follow first-order kinetics , i.e . , cons­
tant fraction of the drug present is eliminated per unit time 
(Goodman and Gilman , 1975) . The elimination of most drugs is 
exponential since drug concentrations usually do not approach 
those required for saturation of the elimination process . Suit­
able dosage regimens for drugs exhibiting dose-dependent kinetics 
in the therapeutic dose range defy easy calculation and are 
established by careful titration of drug level in the patient 
(Levy , 1968) , e.g . , salicylate in cats ( Yeary and Swanson , 1973) . 
In certain exceptional cases , the drug elimination processes 
may become saturated and the result is zero-order kinetics i . e . , 
a constant amount of the drug present is eliminated per unit 
time . An increase in dosage in such cases results in a more 
prolonged half-life and a disproportionately greater accumula-
8 
tion of the drug in the body (Goodman and Gilman, 1975) . The 
elimination of phenylbutazone in dog (Dayton � al . ,  1967) and 
in horses (Piperno � al . ,  1968) obeys zero-order kinetics . The 
rate of elimination of a drug may be influenced by extensive 
binding to plasma protein, the rate of various metabolic pathways 
and the efficiency of excretion processes particularly glomeru­
lar filtration (Baggot, 1977) . 
Principle of Pharmacokinetic Analysis 
Intravenous injection is the most reliable method of admi­
nistration of a drug for the purpose of pharmacokinetic analy­
sis . The biexponential expression (Gibaldi et al . ,  1969; Baggot, 
1977) 
-at 
Cp = Ae 
-{)t 
+ Be (4) 
describes the decline of a drug concentration-time curve after 
intravenous administration of a single bolus dose ( Figure 2) . The 
biexponential expression of the two-compartment open model 
assumes that when injected intravenously, the drug distributes 
instantaneuosly throughout the central compartment . The initial 
steep decline in plasma concentration of a drug is due to the 
distribution of the drug ( by passive diffusion) from the central 
to the peripheral ( tissue) compartment . Once apparent (pseudo) 
distribution equilibrium is attained, the rate of decline in 
plasma drug concentration is decreased and the linear terminal 
portion is referred to as the "()" or the elimination phase . 
Iterative least square linear regression analysis is used to 
find the best fit curve . The slope of the linear terminal portion 
of the curve may be defined as - {)/2 . 303 and an extrapolation of 
40 
A-.... 
20 
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• EXPERIMENTAL 
o RESIDUAL 
DISTR IBUTION 
PHASE 
1 2 3 
Time(h) 
Cp_30e-0.05
8t + 10e-0.0058t 
E LiM IN ATION PHASE 
4 5 6 
FIGURE 2 :  PLASMA CONCENTRATION-TIME PROFILE OF A HYPOTHETICAL 
DRUG AFTER INTRAVENOUS ADMINISTRATION OF A SINGLE 
BOLUS DOSE (From Baggot , J. D .  ( 1977) :  Principles of 
Drug Disposition in Domestic Animals : The Basis of 
Veterinary Clinical Pharma-cology . W .  B. Saunders Co . 
Philadelphia . USA .)  
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this line gives the zero-time intercept , B (mcg/ml) which is an 
estimate of the drug concentration that would have been attained 
if the distribution were instantaneous . 
The residual data points , representing "a" ( the distribution 
phase) are obtained by subtracting the extrapolated portion of "[3" 
( the elimination phase)  from the experimental data of the initial 
steep portion of the concentration-time curve . Least square re-
gression analysis for the residual data is used to obtain the 
best fit curve of the distribution phase "a" and extrapolation of 
this line yields zero-time intercept , A .  
For the three-compartment open model , the second set of 
residual data points are obtained by subtracting the extrapolated 
portion of the first distribution phase from its steep portion . 
Least squares regression analysis for the second set of residual 
data is used to obtained the best fit curve of the second distri-
bution phase "n", the extrapolation yields the zero-time inter-
cept , P (mcg/ml) . 
Actual Pharmacokinetic Rate Constants 
The plasma drug concentration-time curve provides the only 
accurate information for drug measurement in the body . The 
experimental constants ( A ,  B, a and [3) are "hybrid" pharmacokine-
tic parameters and are used to calculate the actual pharmacokine-
tic rate constants (k1 2 , k21 and kel) associa�ed with the two-
compartment open model (Baggot , 1978) . 
k 1 2 = A{3 + Ba 
A + B 
k 2 1 = a + [3 - k21 - k el 
(5 )  
(6)  
1 1  
are the rate constants for distribution between central and 
peripheral compartments, and 
( 7 )  
is the rate constant for elimination . All these expressions are 
given in units of reciprocal time (h1 ) .  
Determination of the microconstants permits an assesment of 
the relative contribution of distribution and elimination pro-
cesses (which may be altered in disease state)  to the concentra-
tion-time profile of a drug (Baggot, 1977) . A computer pro-
gramme, using values of the individual rate constants of the 
model, can be used to predict curves which describe the levels of 
a drug (expressed as fraction of a single dose) in the central 
and peripheral compartments as a function of time, as well as 
elimination curve . Based on the hybrid and actual pharmacokinetic 
parameters, other parameters associated with the two-compartment 
open model can be calculated (Baggot, 1977) . 
Half-life ( t 1/2 ) 
The half-life for the elimination phase or the ( biological) 
half-life of a drug is defined as the time required for the body 
to eliminate one-half of a particular drug, i . e . ,  the time taken 
for the serum concentration of a drug to decline by fifty per 
cent during the elimination phase of the disposition curve . It is 
assumed that once pseudodistribution equilibrium has been esta-
blished, the ratio of the drug in peripheral to central compart-
ments remains constant . The half-life value is obtained from the 
expression, 
t 1/2 = In 2 = 0 . 693 fi fi 
12 
( 8) 
fi is the overall elimination rate constant, t1/2 is expressed 
in unit of time (h) . An estimate of the half-life may also be 
obtained graphically (Figure 3) . A large value of ficorresponds to 
a short half-life and indicates rapid elimination (Baggot, 1977) . 
For drugs that obey zero-order kinetics, their half-lives 
become progressively longer as the doses increase (Baggot, 1978), 
e . g . ,  elimination of phenylbutazone in dogs (Dayton � a1 . ,  1967) 
horses (Piperno � a1 . ,  1968) and salicylate in cats ( Yeary and 
Swanson, 1973) . Knowledge of the half-life is very useful parti-
cular1y for design of rational dosage regimens . 
The half-lives of most drugs are independent of the dose and 
route of administration . Intravenous injection of a single dose 
of the drug is the only satisfactory procedure to determine the 
half-life value since the apparent overall rate of elimination 
following other routes may be influenced by the rate of absorp-
tion (Byron and Notari, 1976) . 
Apparent Volume of Distribution � 
It is defined as the volume of fluid which would be required 
to contain the amount of drug in the body if it was uniformly 
distributed at a concentration equal to that in the plasma . The 
body is assumed to behave as a single homogeneous compartment 
with respect to the drug . The value of Vd serves as a proportio-
nality constant relating the plasma concentration of a drug to 
the amount in the body at any time after distribution equilibrium 
has been attained . Vd can be expressed as, 
